{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:32:15Z","timestamp":1792794735770,"version":"4.5.0"},"reference-count":30,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Alvotech"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,8,3]]},"DOI":"10.1080\/14712598.2025.2538609","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T10:01:44Z","timestamp":1753264904000},"page":"899-912","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["A randomized, double blind, parallel design, repeat dose, 2-arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of a denosumab biosimilar, AVT03, in postmenopausal women with osteoporosis"],"prefix":"10.1080","volume":"25","author":[{"given":"Mamuka","family":"Lortkipanidze","sequence":"first","affiliation":[{"name":"MediclubGeorgia","place":["Tbilisi, Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobie","family":"de Villiers","sequence":"additional","affiliation":[{"name":"Mediclinic Panorama","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Kania","sequence":"additional","affiliation":[{"name":"Velocity Clinical Research","place":["Skierniewice, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Bullo","sequence":"additional","affiliation":[{"name":"Alvotech Swiss AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Jaskiewicz","sequence":"additional","affiliation":[{"name":"Alvotech Swiss AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Stamatakos","sequence":"additional","affiliation":[{"name":"Alvotech Swiss AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masna","family":"Rai","sequence":"additional","affiliation":[{"name":"Alvotech Swiss AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halimu","family":"Haliduola","sequence":"additional","affiliation":[{"name":"Alvotech Swiss AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Otto","sequence":"additional","affiliation":[{"name":"Alvotech Swiss AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abid","family":"Sattar","sequence":"additional","affiliation":[{"name":"Alvotech Swiss AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Leutz","sequence":"additional","affiliation":[{"name":"Alvotech Swiss AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Berti","sequence":"additional","affiliation":[{"name":"Alvotech Swiss AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99817-6_53"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.4103\/jmh.jmh_114_22"},{"key":"e_1_3_8_4_1","unstructured":"World Health Organisation (WHO). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series 843. 2025 Jun 10."},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-021-02772-0"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01622200"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19052999"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031376"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-020-0706-y"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.69"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06482-z"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020970518"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0525-7"},{"key":"e_1_3_8_14_1","unstructured":"European Medicines Agency (EMA). Prolia summary of product characteristics. 2025 [cited 2025 Jun]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/prolia-epar-product-information_en.pdf"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07161-x"},{"key":"e_1_3_8_16_1","unstructured":"US Food and Drug Administration (FDA) Prolia US Prescribing Information. 2024 [cited 2025 Jun]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125320s213lbl.pdf"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009"},{"key":"e_1_3_8_18_1","unstructured":"European Medicines Agency (EMA). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014 [cited 2025 Jun]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae611"},{"key":"e_1_3_8_20_1","unstructured":"U.S. Food and Drug Administration (FDA). Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for Industry; 2015 [2025 Jun 6]. Available from: https:\/\/www.fda.gov\/media\/82647\/download"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjae016"},{"key":"e_1_3_8_22_1","unstructured":"U.S. Food and drug administration (FDA) FDA approves first interchangeable biosimilars to Prolia and Xgeva to treat certain types of osteoporosis and prevent bone events in cancer 2024. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-interchangeable-biosimilars-prolia-and-xgeva-treat-certain-types-osteoporosis-and"},{"key":"e_1_3_8_23_1","unstructured":"European pharmaceutical review European commission grants first-of-a-kind biosimilar approval. 2024 [2025 Jun 10]. Available from: https:\/\/www.europeanpharmaceuticalreview.com\/news\/229320\/european-commission-grants-first-of-a-kind-biosimilar-approval\/#:~:text=The%20European%20Commission%20(EC)%20has authorised%20as%20an%20osteoporosis%20treatment"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jot.2022.06.007"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02840-8"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-022-00954-y"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2505466"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.637"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.251"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30138-9"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2538609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T08:26:10Z","timestamp":1758529570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2538609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,3]]}},"alternative-id":["10.1080\/14712598.2025.2538609"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2538609","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}